NSE · OSELDEVICE
Osel Devices Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹295 Cr with net profit ₹29 Cr — a 9.92% net margin, versus 10.75% the period before.
Shareholding
As of 2026-09-30
- Promoter64.84%
- Public31.72%
- FII0.12%
- DII3.32%
3,541 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.61× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Healthcare · ranked #1 of 86 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,12,785 Cr | 53.6 | 11.85 | 20.48% | 7.91% |
| Manipal Health Enterpri Limited | ₹82,040 Cr | 87.48 | 4.99 | 10.59% | 7.81% |
| Max Healthcare Institute Ltd. | ₹81,271 Cr | 54.29 | 7.56 | 13.42% | 16.73% |
| Aster DM Quality Care Ltd. | ₹56,502 Cr | 145.66 | 13.43 | 8.48% | 6.54% |
| Fortis Healthcare Ltd. | ₹55,467 Cr | 52 | 5.59 | 10.53% | 11.02% |
| Narayana Hrudayalaya Ltd. | ₹33,971 Cr | 39.41 | 7.48 | 17.76% | 9% |
| Global Health Limited | ₹32,588 Cr | 56.93 | 8.2 | 14.05% | 11.88% |
| Dr. Lal Path Labs Ltd. | ₹31,146 Cr | 55.37 | 12.4 | 20.13% | 18.75% |
| Krishna Institute of Medical Sciences Ltd. | ₹28,124 Cr | 134.73 | 7.5 | 10.74% | 4.85% |
| Dr. Agarwal's Health Care Limited | ₹15,068 Cr | 102.2 | 7.44 | 6.58% | 6.72% |
| Osel Devices Limited(this company) | — | 20.46 | 3.14 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashOsel Devices Limited, operating in the Healthcare sector, has a PE ratio of 27.02 and an EPS of 16.43. The company's book value is 107.04 and its ROCE stands at 31.14%. The debt-to-equity ratio is 0.56. The 52-week high for the share price was 835 and the 52-week low was 276.
Positives
- +Revenue has consistently grown, reaching Rs 186.60 Cr in March 2025.
- +Net profit has steadily increased, reaching Rs 20.05 Cr in March 2025.
- +The company's Debt-to-equity ratio is 0.56, indicating a moderate debt load.
- +Return on Capital Employed (ROCE) is 31.14%.
Negatives
- −Promoter shareholding has decreased from 71.53% in March 2025 to 64.84% in June 2026.
- −The company has not disclosed any quarterly results.
- −No information is available regarding the Return on Equity (ROE).
Financial Performance
Osel Devices Limited has demonstrated growth in revenue and net profit over the past few years. Revenue increased from Rs 132.69 Cr in March 2024 to Rs 186.60 Cr in March 2025. Net profit also rose from Rs 12.68 Cr in March 2024 to Rs 20.05 Cr in March 2025. Diluted EPS grew from 10.99 in March 2024 to 14.31 in March 2025.
Profitability & Returns
The company's ROCE is 31.14%. From March 2021 to March 2025, EBITDA has consistently increased, rising from Rs 2.52 Cr to Rs 32.43 Cr. Net profit has also seen a significant increase during this period, growing from Rs 1.36 Cr in March 2021 to Rs 20.05 Cr in March 2025.
Balance Sheet
The company maintains a debt-to-equity ratio of 0.56, indicating a moderate reliance on debt financing. The book value per share is reported as 107.04. Over the years, the company's financial structure has supported its operational growth.
Ownership & Pledges
As of June 30, 2026, promoter shareholding in Osel Devices Limited was 64.84%. Public shareholding stood at 31.42%, while institutions held 3.74%. FII holdings were 0.18% and DII holdings were 3.56%. There are no promoter pledges reported as of June 30, 2026.
Data as of — price: 2026-10-27 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.